CYP1B1'in Karsinogenez ve Tümör Biyolojisindeki Rolü

Velazquez MNR, Parween S, Udhane SS, et al. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase. Biochem Biophys Res Commun 2019;515(1):133–138. doi:10.1016/j.bbrc.2019.05.127

Uehara S, Uno Y, Yamazaki H. Hepatic expression of cytochrome P450 enzymes in non‐human primate species. J Med Primatol 2017;46(6):347–351. doi:10.1111/jmp.12288

Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006;8(1):E101–E111. doi:10.1208/aapsj080112

Im S, Waskell L. The interaction of microsomal cytochrome P450 2B4 with its redox partners, cytochrome P450 reductase and cytochrome b5. Arch Biochem Biophys 2011;507(1):144–153. doi:10.1016/j.abb.2010.10.023

Bosco DD, Rajalakshmi K, Suganya S, et al. Computational prediction and analysis of very high-risk single nucleotide polymorphisms in human cytochrome P450 oxidoreductase gene. bioRxiv 2019. doi:10.1101/590067

Amichot M, Tarès S, Brun‐Barale A, et al. Point mutations associated with insecticide resistance in the Drosophila cytochrome P450 CYP6A2 enable DDT metabolism. Eur J Biochem 2004;271(7):1250–1257. doi:10.1111/j.1432-1033.2004.04025.x

Rydberg P, Olsen L. Predicting drug metabolism by cytochrome P450 2C9: comparison with the 2D6 and 3A4 isoforms. ChemMedChem 2012;7(7):1202–1209. doi:10.1002/cmdc.201200160

Anzenbacher P, Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58(5):737–747. doi:10.1007/pl00000897

Danielson P. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002;3(6):561–597. doi:10.2174/1389200023337054

Greule A, Stok JE, Voss JJD, et al. Unrivalled diversity: the many roles and reactions of bacterial cytochromes P450 in secondary metabolism. Nat Prod Rep 2018;35(8):757–791. doi:10.1039/c7np00063d

Assenat É, Gerbal‐Chaloin S, Larrey D, et al. Interleukin 1β inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology 2004;40(4):951–960. doi:10.1002/hep.20387

Rendić S, Guengerich FP. Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. Chem Res Toxicol 2014;28(1):38–42. doi:10.1021/tx500444e

Mishin V, Gray JP, Heck DE, et al. Application of the Amplex Red/horseradish peroxidase assay to measure hydrogen peroxide generation by recombinant microsomal enzymes. Free Radic Biol Med 2010;48(11):1485–1491. doi:10.1016/j.freeradbiomed.2010.02.030

Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006;6(12):947–960. doi:10.1038/nrc2015

Rendic S, Guengerich FP. Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol 2012;25(7):1316–1383. doi:10.1021/tx300132k

Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P450 enzymes involved in oxidation of drugs, carcinogens and toxic chemicals. J Pharmacol Exp Ther 1994;270(1):414–423. PMID: 8035341

Murray GI. The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol 2000;192(4):419–426. doi:10.1002/1096-9896(2000)9999:9999<::AID-PATH750>3.0.CO;2-0

Miller W.L. Auchus R.J. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011;32(1), 81–151. doi:10.1210/er.2010-0013

McFadyen MC, Melvin WT, Murray GI. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 2004;3(3):363–371. PMID: 15026557

Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57(14):3026–3031. PMID: 9230218

Gomez A, Karlgren M, Edler D, et al. Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics. 2007;8(10):1315–1325. doi:10.2217/14622416.8.10.1315

Murray GI, Patimalla S, Stewart KN, et al. Profiling the expression of cytochrome P450 in breast cancer. Histopathology. 2010;57(2):202–211. doi:10.1111/j.1365-2559.2010.03606.x

Rodriguez-Antona C, Ingelman-Sundberg M, et al. Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006;25(11):1679–1691. doi:10.1038/sj.onc.1209377

Li D, Tolleson WH, Yu D, et al. Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: epigenetic mechanisms in environmental toxicology and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2019;37(3):180–214. doi:10.1080/10590501.2019.1639481

Guengerich FP, et al. Mechanisms of cytochrome P450-catalyzed oxidations. ACS Catalysis. 2018;8(12):10964–10976. doi:10.1021/acscatal.8b03401

Larsen MC, Almeldin A, Tong T, et al. Cytochrome P4501B1 in bone marrow is co-expressed with key markers of mesenchymal stem cells: BMS2 cell line models PAH disruption of bone marrow niche development functions. Toxicol Appl Pharmacol. 2020;401:115111. doi:10.1016/j.taap.2020.115111

Wang A, Savas Ü, Stout C, et al. Structural characterization of the complex between α-naphthoflavone and human cytochrome P450 1B1. J Biol Chem. 2011;286(7):5736–5743. doi:10.1074/jbc.m110.204420

Faiq MA, Dada R, Qadri R, et al. CYP1B1-mediated pathobiology of primary congenital glaucoma. J Curr Glaucoma Pract. 2015;9(3):77–80. doi:10.5005/jp-journals-10008-1189

Li DN, Seidel A, Pritchard MP, et al. Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics. 2000;10(4):343–353. doi:10.1097/00008571-200006000-00008

Sissung TM, Price DK, Sparreboom A, et al. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res. 2006;4(3):135–150. doi:10.1158/1541-7786.mcr-05-0101

Ye G, Li J, Yu W, et al. ALKBH5 facilitates CYP1B1 mRNA degradation via m6A demethylation to alleviate MSC senescence and osteoarthritis progression. Exp Mol Med. 2023;55(8):1743–1756. doi:10.1038/s12276-023-01059-0

Zhu Y, Dutta S, Han Y, et al. Oxidative stress promotes lipid-laden macrophage formation via CYP1B1. Redox Biol. 2025;79:103481. doi:10.1016/j.redox.2024.103481

Zheng W, Jefcoate CR. Steroidogenic factor-1 interacts with cAMP response element-binding protein to mediate cAMP stimulation of CYP1B1 via a far upstream enhancer. Mol Pharmacol. 2005;67(2):499–512. doi:10.1124/mol.104.005504

Faiq MA, Dada R, Sharma R, et al. CYP1B1: a unique gene with unique characteristics. Curr Drug Metab. 2015;15(9):893–914. doi:10.2174/1389200216666150206130058

Sheibani N, Tang Y, Sorenson CM, et al. Endothelium CYP1B1 expression mediates a proangiogenic phenotype. FASEB J. 2008;22(S1). doi:10.1096/fasebj.22.1_supplement.49.1

Li F, Zhu W, Gonzalez FJ, et al. Potential role of CYP1B1 in the development and treatment of metabolic diseases. Pharmacol Ther. 2017;178:18–30. doi:10.1016/j.pharmthera.2017.03.007

Hadia R, Singh V, Solanki N, et al. Unlocking the clinical significance of cytochrome P450 enzymes. Int J Pharm Investig. 2023;14(1):30–38. doi:10.5530/ijpi.14.1.5

Shimada T, Guengerich FP. Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons. Chem Res Toxicol. 2006;19(2):288–294. doi:10.1021/tx050291v

Tang X, Chen S. Epigenetic regulation of cytochrome P450 enzymes and clinical implication. Curr Drug Metab. 2015;16(2):86–96. doi:10.2174/138920021602150713114159

Moorthy B, Miller KP, Jiang W, et al. Role of cytochrome P4501B1 in benzo[a]pyrene bioactivation to DNA-binding metabolites in mouse vascular smooth muscle cells: evidence from 32P-postlabeling for formation of 3-hydroxybenzo[a]pyrene and benzo[a]pyrene-3,6-quinone as major proximate genotoxic intermediates. J Pharmacol Exp Ther. 2003;305(1):394–401. doi:10.1124/jpet.102.044271

Sun Y, Kosinska W, Guttenplan JB. E-cigarette aerosol condensate enhances metabolism of benzo(a)pyrene to genotoxic products, and induces CYP1A1 and CYP1B1, likely by activation of the aryl hydrocarbon receptor. Int J Environ Res Public Health. 2019;16(14):2468. doi:10.3390/ijerph16142468

Giudice A, Barbieri A, Bimonte S, et al. Dissecting the prevention of estrogen-dependent breast carcinogenesis through NRF2-dependent and independent mechanisms. Onco Targets Ther. 2019;12:4937–4953. doi:10.2147/ott.s183192

Li MY, Liu Y, Liu LZ, et al. Estrogen receptor alpha promotes smoking-carcinogen-induced lung carcinogenesis via cytochrome P450 1B1. J Mol Med (Berl). 2015;93(11):1221–1233. doi:10.1007/s00109-015-1300-4

Jacob A, Hartz AMS, Potin S, et al. Aryl hydrocarbon receptor-dependent upregulation of CYP1B1 by TCDD and diesel exhaust particles in rat brain microvessels. Fluids Barriers CNS. 2011;8(1):23. doi:10.1186/2045-8118-8-23

Šmerdová L, Svobodová J, Kabátková M, et al. Upregulation of CYP1B1 expression by inflammatory cytokines is mediated by the p38 MAP kinase signal transduction pathway. Carcinogenesis. 2014;35(11):2534–2543. doi:10.1093/carcin/bgu190

Kumarakulasingham M, Rooney PH, Dundas SR, et al. Cytochrome P450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res. 2005;11(10):3758–3765. doi:10.1158/1078-0432.ccr-04-1848

Harper TA, Morré J, Lauer FT, et al. Analysis of dibenzo[def,p]chrysene-deoxyadenosine adducts in wild-type and cytochrome P450 1B1 knockout mice using stable-isotope dilution UHPLC-MS/MS. Mutat Res Genet Toxicol Environ Mutagen. 2015;782:51–56. doi:10.1016/j.mrgentox.2015.03.007

Leung HY, Yung LH, Shi G, Lu A, Leung LK. The red wine polyphenol resveratrol reduces polycyclic aromatic hydrocarbon-induced DNA damage in MCF-10A cells. Br J Nutr. 2009;102(10):1462–1468. doi:10.1017/s0007114509990481

Chen C, Yang Y, Guo Y, et al. CYP1B1 inhibits ferroptosis and induces anti-PD-1 resistance by degrading ACSL4 in colorectal cancer. Cell Death Dis. 2023;14(4):1–13. doi:10.1038/s41419-023-05803-2

Jennings BL, Anderson LJ, Estes AM, et al. Cytochrome P450 1B1 contributes to renal dysfunction and damage caused by angiotensin II in mice. Hypertension. 2012;59(2):348–354. doi:10.1161/hypertensionaha.111.183301

Su Z, Yao C, Tipper JL, et al. Nanostrategy of targeting at embryonic trophoblast cells using CuO nanoparticles for female contraception. ACS Nano. 2023;17(24):25185–25204. doi:10.1021/acsnano.3c08267

Chun Y, Kwon Y, Kwon T. Human CYP1B1 enhances cancer progression through induction of SP1 via DNMT-mediated epigenetic regulation of miR-375. Cancer Research. 2024;84(7_Suppl):LB296. doi:10.1158/1538-7445.AM2024-LB296

Lewis JM, Bürgler C, Fraser J, et al. Mechanisms of chemical cooperative carcinogenesis by epidermal Langerhans cells. J Invest Dermatol. 2015;135(5):1405–1414. doi:10.1038/jid.2014.411

Cirillo F, Lappano R, Bruno L, et al. AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs). J Exp Clin Cancer Res. 2019;38(1):335. doi:10.1186/s13046-019-1337-2

Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer. 2014;14(12):801–814. doi:10.1038/nrc3846

Carrera AN, Grant M, Zordoky BN. CYP1B1 as a therapeutic target in cardio-oncology. Clin Sci (Lond). 2020;134(21):2897–2927. doi:10.1042/cs20200310

Kwon Y, Baek H, Ye D, et al. CYP1B1 enhances cell proliferation and metastasis through induction of EMT and activation of Wnt/β-catenin signaling via SP1 upregulation. PLoS One. 2016;11(3):e0151598. doi:10.1371/journal.pone.0151598

Lei T, Zhang W, He Y, et al. ZNF276 promotes the malignant phenotype of breast carcinoma by activating the CYP1B1-mediated Wnt/β-catenin pathway. Cell Death Dis. 2022;13(9):780. doi:10.1038/s41419-022-05223-8

Kwon Y, Chun Y. CYP1B1 induces cancer progression through regulation of TRAIL pathway and uPA–uPAR system. Cancer Research. 2019;79(13_Suppl):3469. doi:10.1158/1538-7445.am2019-3469

Kwon Y, Ye D, Baek H, et al. Cyp1b1 induces tumorigenic metastasis through promotion of upar and subsequently activation of upar signaling via regulation of mdm2‐upar system. The FASEB Journal. 2018;32(S1). doi:10.1096/fasebj.2018.32.1_supplement.533.33

Kwon Y, Shin S, Chun Y. Human cyp1b1 induces cancer cell metastasis through sp1-mediated activation of upa-upar signaling pathway. Cancer Research. 2021;81(13_Supplement):2847–2847. doi:10.1158/1538-7445.am2021-2847

Alsubait A, Aldossary W, Rashid M, et al. Cyp1b1 gene: implications in glaucoma and cancer. J Cancer. 2020;11(16):4652–4661. doi:10.7150/jca.42669

Morvan VL, Richard É, Cadars M, et al. Cytochrome p450 1b1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma. Br J Cancer. 2020;123(5):772–784. doi:10.1038/s41416-020-0932-5

Alshammari FOFO, Al–Saraireh Y, Youssef AMM, et al. Cytochrome p450 1b1 overexpression in cervical cancers: cross-sectional study. Interact J Med Res. 2021;10(4):e31150. doi:10.2196/31150

Park Y, Kwon Y, Chun Y. Cyp1b1 activates wnt/β-catenin signaling through suppression of herc5-mediated isgylation for protein degradation on β-catenin in hela cells. Toxicol Res. 2017;33(3):211–218. doi:10.5487/tr.2017.33.3.211

Wan X, Xing Z, Ouyang J, et al. Histomorphological and ultrastructural cadmium-induced kidney injuries and precancerous lesions in rats and screening for biomarkers. Biosci Rep. 2022;42(6). doi:10.1042/bsr20212516

Ma K, Li Q, Zhang Y, et al. Cyp1b1 promotes angiogenesis and sunitinib resistance in clear cell renal cell carcinoma via usp5-mediated hif2α deubiquitination. Neoplasia. 2025;66:101186. doi:10.1016/j.neo.2025.101186

Kwon Y, Park N, Shin S, et al. Induction of sp1 factor by cyp1b1 inhibits trail-mediated apoptotic pathway. Cancer Research. 2014;74(19_Supplement):2754–2754. doi:10.1158/1538-7445.am2014-2754

Merii MH, Fardoun M, Asmar KE, et al. Effect of bpa on cyp450s expression, and nicotine modulation, in fetal rat brain. Neurotoxicol Teratol. 2022;92:107095. doi:10.1016/j.ntt.2022.107095

Zhu Z, Mu Y, Qi C, et al. Cyp1b1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro Int J Mol Med. 2014;35(2):340–348. doi:10.3892/ijmm.2014.2041

Xie S, Tu Z, Xiong J, et al. Cxcr4 promotes cisplatin-resistance of non-small cell lung cancer in a cyp1b1-dependent manner. Oncology Reports. 2016;37(2):921–928. doi:10.3892/or.2016.5289

Cheng H, Sharen G, Wang Z, et al. Lncrna uca1 enhances cisplatin resistance by regulating cyp1b1-mediated apoptosis via mir-513a-3p in human gastric cancer. Cancer Manag Res. 2021;13:367–377. doi:10.2147/cmar.s277399

Zhang B, Chen H, Yang R, et al. Pinocembrin alleviates renal ischemia–reperfusion injury/unilateral ureteral obstruction (uuo)‐generated renal fibrosis by targeting the cyp1b1/ros/mapk axis. FEBS Jl. 2025;292(8):2119–2144. doi:10.1111/febs.17414